Related Experiment Video
Updated: Aug 12, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.8K
Pyoderma gangrenosum and myeloproliferative neoplasms
1Cancer Molecular Diagnostics, St James's Hospital, Dublin, Ireland.
Clinical and Experimental Dermatology
|January 26, 2023
Summary
Testing for myeloproliferative neoplasm mutations is not recommended for pyoderma gangrenosum patients without specific clinical signs. This approach avoids unnecessary molecular testing in most pyoderma gangrenosum cases.
Area of Science:
- Hematology
- Dermatology
- Oncology
Background:
- Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis.
- PG is occasionally linked to hematological malignancies, but rarely to myeloproliferative neoplasms (MPNs).
Approach:
- A review was conducted on requests for molecular detection of MPN driver mutations in patients diagnosed with PG.
- The study analyzed the necessity of genetic testing for MPNs in PG patients.
Key Points:
- Molecular testing for MPN driver mutations in PG patients is often unwarranted.
- Testing is unnecessary when patients lack clinical, hematological, or morphological indicators of MPNs.
Conclusions:
- Routine molecular screening for MPNs in all PG patients is not indicated.
- Targeted testing based on clinical suspicion is a more appropriate strategy for identifying MPNs in PG patients.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
01:27Disorders of Leukocytes
1.0K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.0K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:22Bone Marrow Sampling and Transplants
385
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
385